Back
Compare AU
Compare DRUG vs. GBND
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Betashares Global Green Bond Currency Hedged ETF (GBND). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | GBND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 23 |
Median incremental investment | $740.50 | $1,087.70 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $1,546.50 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | GBND | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | GBND.AX was created on 2019-11-26 by BetaShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Solactive Australian and Global Select Sustainability Leaders Bond TR Index - AUD Hedged, before taking into account fees and expenses. |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | AUD - AUSTRALIA DOLLAR (0 %) EURO-BOBL FUTURE JUN26 (0 %) EURO-BUXL 30Y BND JUN26 (0 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Other (74.40 %) Communication Services (25.60 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | |
Management fee | 0.57 % | 0.49 % |
Key Summary
DRUG | GBND | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Australian and Global Select Sustainability Leaders Bond Hedged to AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.49 % |
Price | $8.71 | $20.62 |
Size | $176.672 million | $217.028 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 2.61 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 28/11/2019 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | GBND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 23 |
Median incremental investment | $740.50 | $1,087.70 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $1,546.50 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | GBND | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | GBND |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |